Grogan Staging Calculator for ATTR Cardiac Amyloidosis

Clinical calculation support · Verify results before clinical use

Biomarker-based staging

Enter the patient's cardiac biomarker values to determine the Grogan stage.

—Grogan stage
Intended population: patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CM). This calculator reproduces the original Grogan biomarker thresholds; it is not the UK/NAC staging system.

Use a reported troponin T result. Troponin I is not interchangeable with this criterion.

Cutoff: 0.05 ng/mL

Equivalent threshold: 50 ng/L. The threshold is applied after unit conversion.

Enter the measured NT-proBNP concentration.

Cutoff: 3,000 pg/mL

pg/mL and ng/L are numerically equivalent for this concentration.

—Stage
Grogan prognostic category
Awaiting input
Enter both biomarkers and select “Calculate stage”.
Biomarker classification

Both biomarker values are required. Values above the specified thresholds are classified as elevated.

The published 4-year overall survival estimates describe the original study cohort and should not be interpreted as an individualized survival prediction.

About the Grogan Staging System

The Grogan staging system is a biomarker-based prognostic classification developed in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CM). It uses two cardiac biomarkers: cardiac troponin T and NT-proBNP.

Variables and thresholds

BiomarkerThresholdElevated when
Troponin T0.05 ng/mL (50 ng/L)>0.05 ng/mL
NT-proBNP3,000 pg/mL (3,000 ng/L)>3,000 pg/mL

Stage classification and reported outcomes

StageBiomarkers above threshold4-year overall survival
INeither (0)57%
IIOne (1)42%
IIIBoth (2)18%

In the original report, stage III was associated with higher mortality than stage I after adjustment for age and sex (hazard ratio 3.6; p < 0.001).

Important application notes

  • The original Grogan cohort comprised patients with ATTRwt; the system should not automatically be applied to ATTR variant (ATTRv) disease as though it had been derived in that population.
  • This tool uses troponin T only. Troponin I is not a substitute for the original TnT criterion.
  • At the exact threshold, a value is classified as not above threshold (≤); a value greater than the threshold is classified as elevated. This follows the threshold convention shown in the ACC staging summary.
  • Biomarker assay characteristics, clinical context, renal function, and changes in treatment era can affect interpretation.
  • The original survival estimates predate current disease-modifying ATTR therapies and should not be used as contemporary individualized prognoses.

References

Grogan M, Scott CG, Kyle RA, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. Journal of the American College of Cardiology. 2016;68(10):1014–1020. DOI: 10.1016/j.jacc.2016.06.033.
Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. Journal of the American College of Cardiology. 2023;81(11):1076–1126. DOI: 10.1016/j.jacc.2022.11.022.
Clinical disclaimer: This calculator is an educational aid for prognostic staging and does not establish the diagnosis of cardiac amyloidosis, determine amyloid subtype, or provide a treatment recommendation. Confirm the diagnosis and ATTR subtype using an appropriate diagnostic pathway. Interpret the stage alongside the patient's clinical status, comorbidities, renal function, biomarker assay, and current treatment. Do not use the historical cohort survival estimates as an individual prediction or as the sole basis for clinical decisions.